Compare HSBC Holdings plc (HSBC) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs IDEXX Laboratories, Inc. — how do they compare? HSBC Holdings plc trades at $92.98 (market cap $311.92B), while IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B). The key difference: HSBC Holdings plc is far larger — about 7.7× IDEXX Laboratories, Inc.'s market cap, and HSBC Holdings plc pays a 4.05% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| HSBC | IDXX | |
|---|---|---|
Market Cap | $311.92B | $40.43B |
Volume | 3,546,658 | 692,164 |
Sector | Financials | Health |
52-Week High | $107.86 | $766.68 |
52-Week Low | $65.67 | $504.70 |
Typical Hold Time | 36 Days | 46 Days |
Enterprise Value | $222.19B | $41.32B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.96, down 0.8% with bearish technical indicators. The bank shows strong profitability with 34.54% net margin and 12.44% ROE, while trading at reasonable valuations (P/E 13.23). Recent earnings show mixed results with Q2 beat but Q1 miss. Analyst sentiment is mixed with 38.1% buy ratings amid strategic expansions in US wealth management and Asian markets.
HSBC presents a balanced opportunity with solid fundamentals offset by near-term technical weakness. Growth initiatives in wealth management and Asian markets provide upside potential, while CFO transition and European restructuring pose execution risks. The stock's valuation remains attractive relative to earnings power.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
